0001209191-21-068408.txt : 20211207
0001209191-21-068408.hdr.sgml : 20211207
20211207183557
ACCESSION NUMBER: 0001209191-21-068408
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211203
FILED AS OF DATE: 20211207
DATE AS OF CHANGE: 20211207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EVNIN LUKE
CENTRAL INDEX KEY: 0001134657
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211477180
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET, 54TH STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Foley Todd
CENTRAL INDEX KEY: 0001473930
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211477179
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET 54TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2014, L.P.
CENTRAL INDEX KEY: 0001609492
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211477181
BUSINESS ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 425-9200
MAIL ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2014 (B), L.P.
CENTRAL INDEX KEY: 0001609493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211477178
BUSINESS ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02124
BUSINESS PHONE: (617) 425-9200
MAIL ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Asset Management Investors BV2014 LLC
CENTRAL INDEX KEY: 0001609495
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211477177
BUSINESS ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 425-9200
MAIL ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BIOVENTURES 2018 (B), L.P.
CENTRAL INDEX KEY: 0001729504
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211477174
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER NAME:
FORMER CONFORMED NAME: MPM BIOVENTURES 2018 (B) LP
DATE OF NAME CHANGE: 20180126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
CENTRAL INDEX KEY: 0001734817
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211477173
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2014 LLC
CENTRAL INDEX KEY: 0001765021
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211477176
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2014 GP LLC
CENTRAL INDEX KEY: 0001765091
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211477175
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iTeos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001808865
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 857-204-4583
MAIL ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-12-03
0
0001808865
iTeos Therapeutics, Inc.
ITOS
0001609492
MPM BioVentures 2014, L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001134657
EVNIN LUKE
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001473930
Foley Todd
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001609493
MPM BioVentures 2014 (B), L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001609495
MPM Asset Management Investors BV2014 LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001765021
MPM BioVentures 2014 LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001765091
MPM BioVentures 2014 GP LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001729504
MPM BIOVENTURES 2018 (B), L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001734817
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
Common Stock
2021-12-03
4
S
0
17569
34.68
D
2917732
I
See Footnote
Common Stock
2021-12-03
4
S
0
2419
35.44
D
2915313
I
See Footnote
Common Stock
2021-12-03
4
S
0
179
36.26
D
2915134
I
See Footnote
Common Stock
2021-12-06
4
S
0
8469
32.35
D
2906665
I
See Footnote
Common Stock
2021-12-06
4
S
0
1171
33.57
D
2905494
I
See Footnote
Common Stock
2021-12-06
4
S
0
508
34.08
D
2904986
I
See Footnote
Common Stock
2021-12-06
4
S
0
60
35.04
D
2904926
I
See Footnote
Common Stock
2021-12-07
4
S
0
17962
33.15
D
2886964
I
See Footnote
Common Stock
2021-12-07
4
S
0
1494
34.11
D
2885470
I
See Footnote
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
The shares were sold as follows: 10,467 by MPM BioVentures 2014, L.P. ("BV 2014"), 359 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,612 by MPM BioVentures 2018, L.P. ("BV 2018") and 131 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.15 to $35.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,651,193 by BV 2014, 97,289 by, 56,834 by AM BV2014, 1,042,857 by BV 2018, 48,966 by BV 2018(B) and 20,593 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 1,441 by BV 2014, 50 by AM BV2014, 910 by BV 2018 and 18 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.15 to $36.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,649,752 by BV 2014, 97,289 by BV 2014(B), 56,784 by AM BV2014, 1,041,947 by BV 2018, 48,966 by BV 2018(B) and 20,575 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 107 by BV 2014, 4 by AM BV2014, 67 by BV 2018 and 1 by AM BV2018.
The shares are held as follows: 1,649,645 by BV 2014, 97,289 by BV 2014(B), 56,780 by AM BV2014, 1,041,880 by BV 2018, 48,966 by BV 2018(B) and 20,574 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 5,046 by BV 2014, 173 by AM BV2014, 3,187 by BV 2018 and 63 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.98 to $32.975 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,644,599 by BV 2014, 97,289 by BV 2014(B), 56,607 by AM BV2014, 1,038,693 by BV 2018, 48,966 by BV 2018(B) and 20,511 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 698 by BV 2014, 24 by AM BV2014, 441 by BV 2018 and 8 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.99 to $33.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,643,901 by BV 2014, 97,289 by BV 2014(B), 56,583 by AM BV2014, 1,038,252 by BV 2018, 48,966 by BV 2018(B) and 20,503 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014, 191 by BV 2018 and 4 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.125 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,643,598 by BV 2014, 97,289 by BV 2014(B), 56,573 by AM BV2014, 1,038,061 by BV 2018, 48,966 by BV 2018(B) and 20,499 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 35 by BV 2014, 2 by AM BV2014, 22 by BV 2018 and 1 by AM BV2018.
The shares are held as follows: 1,643,563 by BV 2014, 97,289 by BV 2014(B), 56,571 by AM BV2014, 1,038,039 by BV 2018, 48,966 by BV 2018(B) and 20,498 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 10,701 by BV 2014, 368 by AM BV2014, 6,759 by BV 2018 and 134 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,632,862 by BV 2014, 97,289 by BV 2014(B), 56,203 by AM BV2014, 1,031,280 by BV 2018, 48,966 by BV 2018(B) and 20,364 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 890 by BV 2014, 31 by AM BV2014, 562 by BV 2018 and 11 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.875 to $34.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,631,972 by BV 2014, 97,289 by BV 2014(B), 56,172 by AM BV2014, 1,030,718 by BV 2018, 48,966 by BV 2018(B) and 20,353 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.
2021-12-07
/s/ Luke Evnin
2021-12-07
/s/ Todd Foley
2021-12-07
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P.
2021-12-07
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC
2021-12-07
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC
2021-12-07
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC
2021-12-07
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018 (B), L.P.
2021-12-07
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC
2021-12-07